Abstract
There have been many exciting developments in this field since the 1st International Symposium was held in Tel Aviv in 1973. Such progress is all the more remarkable considering that the metabolic basis for the first such genetic defects, xanthinuria and hereditary oroticaciduria, was established as recently as 1959 and by 1973 the number had increased only to include complete or partial deficiency of hypoxanthine-guanine phosphoribosyltransferase: HPRT) and superactivity of its companion X-linked disorder, phosphoribosylpyrophosphate synthetase (PRPS). Both owed their recognition then, as now, to the fact that they can present as gout, kidney stones or hyperuricaemia (1). Allopurinol had made its appearance as a uric acid lowering drug for treating hyperuricaemia, and the mechanisms of the altered renal urate handling in the so-called ‘primary gout’ of the middle aged male were being hotly debated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
